Immatics N.V. (IMTX)
4.04
0.52 (14.77%)
At close: Apr 09, 2025, 3:59 PM
3.83
-5.00%
After-hours: Apr 09, 2025, 06:32 PM EDT
14.77% (1D)
| Bid | 3.01 |
| Market Cap | 490.45M |
| Revenue (ttm) | 156.01M |
| Net Income (ttm) | 15.2M |
| EPS (ttm) | 0.15 |
| PE Ratio (ttm) | 26.9 |
| Forward PE | -4.25 |
| Analyst | Buy |
| Ask | 4.5 |
| Volume | 892,051 |
| Avg. Volume (20D) | 985,824 |
| Open | 3.46 |
| Previous Close | 3.52 |
| Day's Range | 3.45 - 4.11 |
| 52-Week Range | 3.30 - 13.77 |
| Beta | 0.85 |
About IMTX
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I ...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 12, 2018
Employees 554
Stock Exchange NASDAQ
Ticker Symbol IMTX
Website https://www.immatics.com
Analyst Forecast
According to 4 analyst ratings, the average rating for IMTX stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 296.53% from the latest price.
Stock ForecastsNext Earnings Release
Immatics N.V. is scheduled to release its earnings on May 13, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+3.97%
Immatics shares are trading higher after the compa...
Unlock content with
Pro Subscription
6 months ago
-15.54%
Immatics shares are trading lower after the company announced a $150 million proposed public offering of its ordinary shares.
